Phase I study of BMS-986299, an NLRP3 agonist, as monotherapy and in combination with nivolumab and ipilimumab in patients with advanced solid tumors.

J Immunother Cancer · 2025 · PMC11749293 · PMID 39824531

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

In NI lesions, CD163+ TAMs had an increasing trend (6/11, 54%, MFC: 1.1) and little change was observed in TANs (3/11, 27%, MFC: 2.2).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.